You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for New Drug Application (NDA): 210557


✉ Email this page to a colleague

« Back to Dashboard


NDA 210557 describes VYLEESI (AUTOINJECTOR), which is a drug marketed by Cosette and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the VYLEESI (AUTOINJECTOR) profile page.

The generic ingredient in VYLEESI (AUTOINJECTOR) is bremelanotide acetate. One supplier is listed for this compound. Additional details are available on the bremelanotide acetate profile page.
Summary for 210557
Tradename:VYLEESI (AUTOINJECTOR)
Applicant:Cosette
Ingredient:bremelanotide acetate
Patents:5
Pharmacology for NDA: 210557
Mechanism of ActionMelanocortin Receptor Agonists
Suppliers and Packaging for NDA: 210557
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557 NDA Palatin Technologies 80064-141 80064-141-02 2 SYRINGE in 1 CARTON (80064-141-02) / .3 mL in 1 SYRINGE (80064-141-01)
VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557 NDA Palatin Technologies 80064-141 80064-141-04 4 SYRINGE in 1 CARTON (80064-141-04) / .3 mL in 1 SYRINGE (80064-141-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;SUBCUTANEOUSStrengthEQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)
Approval Date:Jun 21, 2019TE:RLD:Yes
Regulatory Exclusivity Expiration:Jun 21, 2024
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:⤷  Sign UpPatent Expiration:Nov 5, 2033Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
Patent:⤷  Sign UpPatent Expiration:Apr 29, 2041Product Flag?Substance Flag?Delist Request?
Patented Use:TREATING ACQUIRED, GENERALIZED HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN A PREMENOPAUSAL FEMALE PATIENT WITH CONTROLLED HYPERTENSION BY INJECTING BREMELANOTIDE MORE THAN ONCE WITH AT LEAST 24 HOURS BETWEEN DOSES AND NO MORE THAN 8 DOSES PER MONTH

Expired US Patents for NDA 210557

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cosette VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.